Skip to main content
Article thumbnail
Location of Repository

Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts

By Stacey L Tannheimer, Clifford D Wright and Michael Salmon
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3342220
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2009). AF: The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood
    2. (2005). Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J
    3. (2006). al: Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to Tannheimer et al.
    4. (2007). al: Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol
    5. (2002). AR: Regulation of RANTES promoter activation in alveolar epithelial cells after cytokine stimulation.
    6. (2007). BB: PGE2 inhibition of TGF-b1-induced myofibroblast differentiation is Smadindependent but involves cell shape and adhesion-dependent signaling.
    7. (2011). BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med
    8. (2005). Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med
    9. (2004). Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease.
    10. (2003). Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.
    11. (2011). DS: Small airway disease in asthma and COPD: clinical implications. Chest
    12. (2011). EA: Endothelin in pulmonary fibrosis.
    13. (2009). Eickelberg O: TGF-beta signalling in COPD: deciphering genetic and cellular susceptibilities for future therapeutic regimens. Swiss Med Wkly
    14. (2002). et al: Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
    15. (2009). et al: PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-b1-stimulated fibroblasts.
    16. (2010). Fabbri LM: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res
    17. (2009). FJ: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized trials. Lancet
    18. (2010). GA: A phosphodiesterase 4 inhibitor, roflumilast Noxide, inhibits human lung fibroblast functions in vitro. Pulm Pharmacol Ther
    19. (2003). JA: TGF-beta1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax
    20. (2007). Leask A: Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum
    21. (2010). LS: The role of the transcription factor CREB in immune function.
    22. (2003). M: C-Jun-NH2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-b1 in human lung fibroblasts.
    23. (2003). Mauviel A: Cyclic adenosine 3’,5 ’-monophosphate-elevating agents inhibit transforming growth factor-β-induced SMAD3/4-dependent transcription via a protein kinase Adependent mechanism. Oncogene
    24. (2004). Moens U: What turns CREB on ? Cell Signal
    25. (2006). Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.
    26. (2009). Morcillo EJ: Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
    27. (2004). Pathophysiology of airflow limilation in chronic obstructive pulmonary disease. Lancet
    28. (2010). Prostaglandin E2 activates cAMP response element-binding protein in glioma cells via a signaling pathway involving PKA-dependent inhibition of ERK. Prostaglandins & Other Mediators
    29. (2009). Rabe KF: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet
    30. (2010). Schermuly RT: Effects of phosphodiesterase 4 inhibition on bleomycininduced pulmonary fibrosis in mice. Pulm Med
    31. (2006). Sidawy AN: Transforming growth factor-beta and wound healing. Perspect Vasc Surg Endovasc Ther
    32. (2008). Small airways: an important but neglected target in the treatment of obstructive airway diseases. Tr Pharmacol Sci
    33. (2011). Small-airway obstruction and emphysema in chronic obstructive pulmonary disease.
    34. (2007). The myofibroblast: one function, multiple origins.
    35. (2010). The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther
    36. (2004). Therapeutic responses in asthma and COPD.
    37. (1993). Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts.
    38. (2001). Umeda A: Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med
    39. (2000). Wrana JL: Smads as transcriptional co-modulators.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.